Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known		
Application Number	09/927,422	
Filing Date	August 10, 2001	
First Named Inventor	Gary VAN NEST	
Art Unit	1645	
Examiner Name	N. Minnifield	
Attorney Docket Number	377882001420	

	U.S. PATENT DOCUMENTS				
	0.11-	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Examiner Cite Initiats* No.	Cite No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	1.	US-2002/0055477-A1	05-09-2002	Nest et al.	
	2.	US-2003/0059773-A1	03-27-2003	Van Nest et al.	
	3.	US-5,629,158-A	05-13-1997	Uhlen	
	4.	US-5,770,434-A	06-23-1998	Huse	
	5.	US-5,824,812-A	10-20-1998	Nantz et al.	
	6.	US-6,352,975-B1	03-05-2002	Schreiner et al.	
	7.	US-6,355,267-B1	03-12-2002	Collins	
	8.	US-6,465,188-B1	10-15-2002	Gold et al.	
	9.	US-6,559,129-B1	05-06-2003	Kasid et al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	10.	WO-03/015816-A1	02-27-2003	Dynavax Technologies Corporation		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>3</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	11.	Agrawal, S. et al. (Febraury 2000). "Antisense Therapeutics: is it as Simple as Complementary Base Recognition?," <i>Molecular Med. Today</i> 6:72-81.			
	12.	Busquets, M.A. et al. (November 2003). "Peptides and Liposomes: From Biophysical to Immunogenic Studies," Current Drug Targets 4(8):633-642.			
	13.	Crooke, S.T. (1998). "Basic Principles of Antisense Therapeutics," Chapter 1 In Antisense Research and Application, Crooke, S.T. ed., Springer-Verlag: Berlin, Germany, pp. 1-50.	÷		
	14.	Du Bois, R.M. (October 21, 1999). "Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis," <i>New England Journal of Medicine</i> 341(17):1302-1304.			
	15.	Fearon, K. et al. (2003). "A Minimal Human Immunostimulatory CpG Motif That Potently Induces IFN-y and IFN-q Production," <i>Eur. J. Immunol.</i> 33:2114-2122.			
	16.	Fix, M. et al. (2002). "The Fluorosome The Technique for Investigating Membrane On- and Off- Loading of Drugs by β-CD and Sonicated SUV," FEBS Letters 516:109-112.			
	17.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07848 filed March 12, 2001, three pages.			
<u> </u>	18.	International Search Report mailed on August 27, 2002 for PCT Application No. PCT/US01/25364 filed August 13, 2001, four pages.			
	19.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07843 filed March 12, 2001, three pages.			
	20.	Li, Q.T. et al. (1993). "Effect of Cholesteryl Ester on the Distribution of Fluorescent Cholesterol Analogues in Triacylglycerol-rich Emulsions," <i>Biochimica et Biophysica Acta</i> 1166(2/3):145-			

	·		
Examiner		Date	
Signature	<u></u>	Considered	

SEP 0.7 2006 Sheet

Substitute for form 1449/PTO

2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necess ary)

Application Number	09/927,422
Filing Date	August 10, 2001
First Named Inventor	Gary VAN NEST
Art Unit	1645
Examiner Name	N. Minnifield
Attorney Docket Number	377882001420

Complete if Known

	153.
21.	Peracchi, A. (2004). "Prospects for Antiviral Ribozymes and Deoxyribozymes," Rev. Med. Virol. 14:47-64.
22.	Stayton, P.S. et al. (2000). "Molecular Engineering of Proteins and Polymers for Targeting and Intracellular Delivery of Therapeutics," <i>J. Controlled Release</i> 65:203-220.
23.	Van Uden, J. et al. (November 1999). "Immunostimulatory DNA and Applications to Allergic Disease," <i>Journal of Allergy and Clinical Immunology</i> 104(5):902-910.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

2

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.